Prescription digital therapeutics (PDTs) are health software, available by prescription only, intended to treat or alleviate a disease, disorder, condition, or injury by generating and delivering a medical intervention that has a demonstrable positive therapeutic impact on a patient’s health.
PDTs offer significant promise in treating certain conditions and improving access to care, but participants
agreed that a new modality requires new approaches to coverage. This brief is intended to help prepare the American health care system to begin covering PDTs.
The role of digital therapeutics, software that delivers clinical benefits and prevents, manages, and treats medical conditions, has evolved in the past few years. Explore these resources from AMCP, AMCP Learn, and Journal of Managed Care & Specialty Pharmacy resources to learn more about these innovative therapies.
The Digital Therapeutics Advisory Group is focused on developing resources for payers on when they should evaluate products, what manufacturers should communicate, and understanding how Digital Therapeutics are included in drug compendia. This advisory group is active from March 2022-February 2023.
Partnership Forum: This forum identified challenges and payer needs related to the evidence for digital therapeutics. The forum explored the current market space for digital therapeutics including the evidence for the products, place in therapy, monitoring or utilization metrics and barriers that patients face in obtaining therapies.